# National Brain Tumor Society

National Brain Tumor Society is an Asset Manager based in Newton, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Newton, United States
- **Region:** North America
- **Address:** 55 Chapel Street, Suite 006, Newton, MA 02458
- **Founded:** 2008
- **Assets under management:** Undisclosed
- **Website:** braintumor.org
- **LinkedIn:** https://www.linkedin.com/company/national-brain-tumor-society

## Regulatory record

- **Reports private funds:** No

## About

National Brain Tumor Society focuses on providing information, online programs, and support to individuals with brain tumors. The organization funds research to develop new therapies for adult and pediatric brain tumors. It also advocates for patients, families, caregivers, healthcare professionals, and researchers.

## Sectors

- Healthcare Services
- AI/ML
- Digital Health
- Enterprise Software

## People

- David Arons — President and CEO

## Questions

### Who runs investment decisions at the National Brain Tumor Society?

John Higgins serves as the Managing Director of the Brain Tumor Investment Fund, overseeing the deployment of capital into early-stage drug-development startups. David Arons, the President and CEO, leads the broader organization and represents the Society on the NCI Council of Research Advocates.

### How does the Brain Tumor Investment Fund source its deals?

The fund sources deals through a network of co-investors and research collaborators, including the Yale Cancer Center via the DNA Damage Response Consortium and the clinical research organization IQVIA. This consortium structure provides access to pre-venture academic discoveries. The Society’s co-founding role in the Jumpstarting Brain Tumor Drug Development Consortium further extends its reach into translational research networks.

### Does the National Brain Tumor Society operate like a traditional venture firm?

No. It functions as a non-profit disease advocacy organization with an embedded investment fund. While it pursues direct equity and convertible-note positions in for-profit startups, the capital derives from donations and grants tied to its 501(c)(3) mission, not from limited partners. This hybrid model aligns financial returns with a charitable mandate to accelerate brain tumor treatments.

### What investment stage does the Brain Tumor Investment Fund target?

The fund targets early-stage, start-up companies — specifically at the translational frontier where academic discoveries require funding to reach clinical trial readiness. Its instruments include direct equity and convertible notes, designed for companies that traditional biotech venture capital often considers too early or too narrow in disease focus.

## Related profiles

- [National Bank Investments](https://altss.com/profile/national-bank-investments)
- [National Capital](https://altss.com/profile/national-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/national-brain-tumor-society

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology